RNS Number : 7360T

GlaxoSmithKline PLC

16 October 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	1,605.036
£15.2750	831.931
£15.2750	2,740.030
£15.2750	4,439.830

d)

Aggregated information

Aggregated volume Price

9,616.827

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	1,249.200
£15.2750	1,600.015
£15.2750	1,529.167

d)

Aggregated information

Aggregated volume Price

4,378.382

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	319.540
£15.2750	402.745
£15.2750	1,147.102

d)

Aggregated information

Aggregated volume Price

1,869.387

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	2,716.836
£15.2750	2,942.442
£15.2750	2,427.360

d)

Aggregated information

Aggregated volume Price

8,086.638

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	605.675
£15.2750	660.007
£15.2750	563.370

d)

Aggregated information

Aggregated volume Price

1,829.052

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
$41.02	415.800
$41.02	83.187
$41.02	641.729
$41.02	1,036.064

d)

Aggregated information

Aggregated volume Price

2,176.780

$41.02

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	993.680
£15.2750	1,160.005
£15.2750	1,094.561

d)

Aggregated information

Aggregated volume Price

3,248.246

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, HR

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	1,324.911
£15.2750	1,460.009
£15.2750	1,207.230

d)

Aggregated information

Aggregated volume Price

3,992.150

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	766.560
£15.2750	840.010
£15.2750	756.529

d)

Aggregated information

Aggregated volume Price

2,363.099

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
$41.02	1,132.956
$41.02	1,314.438
$41.02	1,154.472

d)

Aggregated information

Aggregated volume Price

3,601.866

$41.02

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	2,755.819
£15.2750	3,400.038
£15.2750	3,138.824

d)

Aggregated information

Aggregated volume Price

9,294.681

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.2750	169.685
£15.2750	160.363
£15.2750	150.569

d)

Aggregated information

Aggregated volume Price

480.617

£15.2750

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END DSHEQLFFDBFXFBX